Full Press Release Details
DNA Sciences Announces
and Appointment of New Directors
2006 (Stony Brook, New York)-Applied
DNA Sciences, Inc. (OTC BB: APDN),
security solutions company ("APDN"), today announced that Peter Brocklesby
resigned his position as a director and President of APDN and APDN (B.V.I.)
Inc., its wholly owned subsidiary, and Lawrence Lee resigned his position as
director and Chief Technology Strategist of APDN, effective March 22, 2006,
pursue other interests. APDN also announced that Dr. James A. Hayward, our
Executive Officer, and Dr. Sanford R. Simon have been appointed to the Board
Directors of APDN, effective March 17, 2006.
Hayward has been our acting Chief Executive Officer since October 5, 2005.
June 2004, Dr. Hayward has been the Chairman of Evotope Biosciences, Inc.,
drug development company based in Stony Brook, New York. Since 2001, Dr. Hayward
has been a director of Q-RNA, Inc., a biotech company based in New York, New
York. Since 2000, Dr. Hayward has been a General Partner of Double D Venture
Fund, a venture capital firm based in New York, New York. Between 1990 and
2004, Dr. Hayward was the Chairman, President and CEO of The Collaborative
Group, Ltd., a provider of products and services to the biotechnology,
pharmaceutical and consumer-product industries based in Stony Brook, New York.
Dr. Hayward received his bachelor's degree in Biology and Chemistry from the
State University of New York at Oneonta in 1976, his Ph.D. in Molecular Biology
from the State University of New York at Stony Brook ("Stony Brook") in 1983,
and an honorary Doctor of Science from Stony Brook in 2000. Dr. Hayward has
served on the boards of the Council on Biotechnology, the Long Island
Association, the Stony Brook Foundation, The Research Foundation of State
University of New York Board of Directors, New York Biotechnology Association
and the Long Island Life Sciences Initiative.
believe the collective expertise in the biotechnology, pharmaceutical, and
consumer product industries of our new board members adds comprehensive depth
our board of directors that will serve us well as we continue to advance through
this important stage of development," said James A. Hayward, CEO of APDN. "We
also believe it is critical for the company to have excellent relations with
biotechnology industry, the university and the government to ensure that we
well-positioned to achieve our development goals."
Sanford R. Simon has over 40 years' experience in biochemistry and cell biology
as well as applied genetic research. He has been a Professor of Biochemistry,
Cell Biology and Pathology at Stony Brook since 1997. He joined the faculty
Stony Brook as an Assistant Professor in 1969 and was promoted to Associate
Professor with tenure in 1975. Dr.
was a member of the Board of Directors of The Collaborative Group from 1995
1967 to 1969 Dr. Simon was a Guest Investigator at Rockefeller University.
Simon received a B.A. in Zoology and Chemistry from Columbia University in
a Ph.D. in Biochemistry from Rockefeller University in 1967, and studied
as a postdoctoral fellow with Nobel Prize winner Max Perutz in Cambridge,
England. Dr. Simon's research efforts, which currently include development
of vaccines and small molecule therapeutics for biodefense applications, have
been funded over the past several years in part by grants from the National
Institutes of Health and the Department of Defense. Dr.
is also the principal investigator on a project entitled "A Chimeric Method
System for DNA Encryption and Authentication", funded jointly by APDN, Stony
Brook's Center for Biotechnology and the New York State Office of Science,
Technology and Academic Research.
stated: "I am very pleased to be able to contribute to the direction of this
company, and I look forward to offering my background in biochemistry and cell
biology as a resource for the Board and management team of APDN."
Applied DNA Sciences, Inc.
DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded security solutions
that use plant DNA to verify authenticity and protect corporate and government
agencies from counterfeiting, fraud, piracy, product diversion, identity theft
and unauthorized intrusion into physical plant and databases. Our
common stock is listed on the Over-The-Counter Bulletin Board under the symbol
MeiLin Wan, Applied DNA Sciences, Inc., 25 Health Sciences Drive, Stony Brook,
New York 11790; Tel: 631-444-6861; Fax: 631-444.8848 www.ADNAS.com.
statements made by Applied DNA Sciences, Inc. in this press release may be
forward-looking in nature and are made pursuant to the safe harbor provisions
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements describe the Company's future plans, projections, strategies and
expectations, and may be identified
words such as "expects", "anticipates", "intends", "plans"," "believes",
"seeks", "estimates" or words of similar meaning. These forward-looking
statements are based
assumptions and involve a number of risks, uncertainties, situations and other
factors that may cause our or our industry's actual results, level of activity,
performance or achievements to be materially different from any future results,
level of activity, performance or achievements expressed or implied by these
statements. These factors include changes in interest rates, market competition,
changes in the local and national economies, and various other
from time to time in Applied DNA Sciences' SEC reports and filings, including
our Annual Report on Form 10-KSB, filed on January 12, 2006, and subsequent
Quarterly Reports on Form 10-QSB and Current Report on Form 8-K.
Company undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated